Stifel analyst Alex Thompson reiterated a Buy rating on Pliant Therapeutics (NASDAQ: PLRX).The analyst comments "PLRX announced topline data from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE